Certain patient populations require special consideration
Conclusions The study findings indicate that the use of GLP-1 receptor agonists is not associated with an increased risk of self-harm, suicidal ideation, and suicide as compared to DPP-4 and SGLT-2 inhibitors among T2D patients
There's also an active federal rulemaking worth understanding if you're weighing a compounded GLP-1 program in mid-2026: April 30, 2026 - FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the list of bulk drug substances that large-scale 503B outsourcing facilities may use to compound medications outside a declared drug shortage May 1, 2026 - proposal published in the Federal Register (91 Fed
In addition to writing for Everyday Health, her work has bee
B.HaydenP
Entity 2 - Independent Licensed Clinicians: According to Omzo's published materials, clinical services are provided by third-party networks of U.S.-licensed clinicians who determine eligibility for GLP-1 treatment based on medical history and provider assessment